Worldwide Anti-Asthma Drugs Market to Around USD 18.9 billion as of 2015 which is expected to reach USD 28.3 billion as of 2022

Anti-Asthma Drugs Market

Market Research Future published a Half_Cooked research report on “Global Anti-Asthma Drugs  Market Research Report – Forecast to 2022”– Market Analysis, Scope, Trends and Forecast to 2022

During last decade, respiratory diseases has gained a huge attention thus, many companies have adopted the organic strategy of product launch, acquisition and other. Many companies are operating in the market, however, the major companies dominated the major share in the market due to well-developed brand identity. Now-a-days, there is a significant increase in the number of the company offering anti-asthma drugs.  Thus companies are adopting the new strategies to minimize the competition and increase the market. Some major companies are focusing on development of new and advanced products to gain the market share. Whereas, some are has used the technique of acquisition and collaboration to gain the market. Introduction of the generic drugs has driven the market growth.

Some of the key players in anti-asthma drugs market are:  GlaxoSmithKline plc. (U.K), Merck & Co., Inc. (U.S.), AstraZeneca plc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Teva Pharmaceutical Industries (Taiwan), Novartis International AG (Switzerland), Boehringer Ingelheim (Germany), and Sunovion Pharmaceuticals Inc. (U.S.).

Get a sample report at .

Latest Industry Updates

Being a competitive market, a number of different manufacturer are focusing on the product launch, and acquisition for the market development. Some of the latest development in the market are-

Sept 2017, GlaxoSmithKline plc, a British pharmaceutical company, recently launched three-in-one inhaler for chronic lung disease, to keep its lead in respiratory medicine despite falling sales of the older drug Advair. In 2015, the company has launched Arnuity Ellipta (fluticasone furoate inhalation powder) and Incruse Ellipta (umeclidinium bromide inhalation powder) for the treatment of Asthma.

May 2017, AstraZeneca plc an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company launched a new drug benralizumab which can help some severe asthma patients cut down on or even stop the unsavory steroid pills.

Global Anti-Asthma Drugs Market – Overview

Asthma is a chronic disease involving the airways in the lungs which allow air to come in and out of the lungs. During last few years there is a significant increase in the prevalence of asthma. It is thought that combination of genetic and environmental factors are responsible for causing asthma. Different diagnostic techniques based on the pattern of symptoms, response to therapy over time, and spirometry are used. A potential for growth exists for anti-asthma drugs market owing to rise in patients suffering from asthma and the explosive rise in pollution levels particularly particulates. According to the Global Initiative for Asthma (GINA), in 2013, over 300 million patients globally were suffering from asthma. Additionally, increasing awareness and rising healthcare expenditure have fuelled the growth of the market. Geriatric population and changing environment is considered as an important factor for causing asthma. Rapidly increasing geriatric population and increasing government support for the research & development have boosted the market growth. On the other hand, patent expiration of leading brands, such as Advair and Symbicort, delayed commercialization and marketing of asthma generic alternatives is expected to slow the growth of the market.

Currently, total cure of asthma is not available in the market. Present drugs can only prevent or minimize the symptoms of the asthma, thus the companies in the market can gain the market by launching novel products for the treatment of the disease.

Browse Complete Report at .

Regional Analysis

Depending on geographic region, anti-asthma drugs market is segmented into four key regions: Americas, Europe, Asia-Pacific and Middle East and Africa. Americas dominated the global anti-asthma drug market owing to increasing number of patients suffering form asthma and presence of leading players of the maker in this region. Additionally, rising geriatric population and increasing government support favors the growth of this market in Americas. Europe is the second leading region for the market. Availability of funds and strong government support have fuelled the market growth. Asia-Pacific market is expected to show fastest growth in the anti-asthma drugs market during the forecasted period. Huge patient population, rapidly growing economy, and opportunity for the development of the market have driven the growth of this market in Asia-Pacific. The Middle East and Africa show steady growth in this market due to the presence of poor economy, especially, in the Africa region. The market of this region is dominated by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. However, Africa region shows the fastest growth for the market owing to the presence of huge opportunity for the market.

About us

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

P: +1 646 845 9312


Leave a Reply

Your email address will not be published. Required fields are marked *